多西紫杉醇和顺铂联合治疗晚期非小细胞肺癌的效果及对生存率和毒副反应的影响

Effect of docetaxel combined cisplatin treatment of advanced non-small cell lung cancer and influence on survival rate and toxic side reaction

目的研究多西紫杉醇和顺铂联合治疗晚期非小细胞肺癌的效果及对生存率和毒副反应的影响。方法选取我院于2008年4月~2012年4月收治的晚期非小细胞肺癌患者78例,将其随机分成研究组与对照组,各39例。研究组给予多西紫杉醇与顺铂联合治疗,对照组单纯采用顺铂进行治疗,对两组患者的治疗效果,生存率及毒副反应进行对比分析。结果研究组与对照组的治疗总有效率分别为51.28%（20/39）、23.08%（9/39）,两组比较差异有统计学意义（P〈0.05）;研究组与对照组患者的中位生存时间为（12.6±1.8）个月、（8.2±1.6）个月,研究组与对照组患者1年的生存率分别为48.72%（19/39）、28.21%（11/39）,两组比较差异有统计学意义（P〈0.05）;研究组与对照组治疗后的毒副反应相比较,差异无统计学意义（P〉0.05）。结论采用紫杉醇联合顺铂对晚期非小细胞肺癌患者具有一定的治疗意义,有效延长患者的生存时间,且不会增加毒副作用,是治疗晚期非小细胞肺癌的有效方法,值得临床推广与应用。

Objective To study the effect of docetaxel combined cisplatin in the treatment of advanced non- small cell lung cancer and the influence of which on survival rate and toxic side reaction. Methods 78 patients with advanced non-small cell lung cancer, who were received and treated in our hospital from April 2008 to April 2012, were selected and were randomly divided into study group and control group, with 39 cases in each group. Study group was treated with docetaxel combined cisplatin, while control group was treated with single cisplatin. To comparatively analyze the treatment effect, the survival rate, and the toxic side reaction of patients between the two groups. Results The differences of total treatment effective rate was statically significant compared with study group[51.28%（20/39）] and control group[23.08%（9/39）]（P 〈0.05）. The differences of median survival time and 1 year survival rate were statically significant compared with study group[（12.6 ~ 1.8）months, 48.72%（19/39）] and control group[（8.2 ＋ 1.6）months, 28.21%（11/39）] （P 〈 0.05 ）. The differences of toxic side reaction after treatment between the two groups was no statically significant（P 〉 0.05）. Conclusion Docetaxel combined cisplatin in the treatment of advanced non-small cell lung cancer has certain therapeutic significance, could effectively lengthen the survival time of patients, and would not increase toxic side reaction, is effective method to treat advanced non-small cell lung cancer, is worthy of clinical popularization and application.